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Translocations of the histone-lysine N-methyltransferase 2A (KMT2A) gene, formerly known
as myeloid lymphoid leukemia/mixed-lineage leukemia gene, are commonly associated with
high-risk de novo or therapy-associated B-cell and T-cell lymphoblastic leukemias and myeloid
neoplasms. Rare B-cell non-Hodgkin lymphomas harboring KMT2A translocations have been
reported, but information regarding the clinical behavior of such cases is limited. Here, we
describe two extranodal diffuse large B-cell lymphomas (DLBCLs): a primary thyroid DLBCL
and a large cell transformation of a splenic marginal zone lymphoma, which displayed complex
karyotypes and translocations involving chromosome 11q23 targeting the KMT2A gene. The
pathological and clinical characteristics of these cases are discussed in the context of previously
reported lymphomas associated with different types of KMT2A genetic aberrations. In contrast
to the poor clinical outcomes of patients with acute leukemias andmyeloid neoplasms associated
with KMT2A translocations, patients with B-cell non-Hodgkin lymphomas, exhibiting similar
translocations, appear to respond well to immunochemotherapy. Our findings add to the
growing list of histone methyltransferase genes deregulated in DLBCL and highlight the
diversity of mechanisms, altering the function of epigenetic modifier genes in lymphomas.
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Diffuse large B-cell lymphomas (DLBCLs) are the most
common type of non-Hodgkin lymphomas (NHLs),
accounting for over 30% of all NHL. These neoplasms
comprise a heterogeneous group with respect to morphologic,
phenotypic, and genetic characteristics [1,2], which is
reflected in their disparate clinical behaviour and response
to therapy (overall 5-year survival range 10–60%) [3].
Despite extensive investigations into the genetic underpin-
nings of DLBCLs over the past couple of decades, the
molecular mechanisms involved in disease initiation and
progression are still not well understood. Most DLBCLs are
characterized by complex karyotypes including multiple
chromosomal gains, losses, and translocations [4,5].
Cytogenetic aberrations of the histone-lysine N-methyl-
transferase 2A (KMT2A) gene, previously also referred to
as the myeloid lymphoid leukemia/mixed-lineage leukemia
(MLL), trithorax-like protein, CXXC-type zinc finger
protein 7 and zinc finger protein HRX gene, amongst
others, have been extensively studied in B-cell and T-cell
lymphoblastic leukemias, acute myeloid leukemias and
myelodysplastic syndromes, where they have been impli-
cated in disease pathogenesis [6]. Although chromosome
11q abnormalities are not infrequent in B-NHL [7], little
is known about the presence or frequency of KMT2As, Ltd.aberrations and their prognostic impact in these neoplasms,
primarily due to the rarity of well documented cases [8–11].
Here, we describe two unusual extranodal diffuse large B-cell
lymphomas associated withKMT2A translocations, comprising
a primary thyroid DLBCL and a large cell transformation of
splenic marginal zone lymphoma (SMZL). These cases
inform us of the broad range of neoplasms associated with
KMT2A aberrations and suggest interrogation of the KMT2A
gene by cytogenetic or genomic analysis when chromosome
11q23 abnormalities are encountered in B-NHL. Such analyses
will reveal the spectrum of lymphomas associatedwithKMT2A
aberrations and provide further insights into the role ofKMT2A
in mature B-cell neoplasia.Case summaries
Case 1
A 70-year-old male with hypertension and long standing
hypothyroidism presented to our institution due to a rapidly
enlarging right neck mass causing hoarseness and upper
airway obstruction, over a 6-month period. On physical
examination, diffuse enlargement of the thyroid gland was
noted, but no lymphadenopathy or organomegaly was
evident. Computerized tomography scan of the neck
demonstrated a mass arising in the thyroid and extending into
240 T Gindin et al.cervical soft tissue. An incisional biopsy was performed,
which disclosed a DLBCL. The patient was treated with six
cycles of R-CHOP chemotherapy (cyclophosphamide,
hydroxydaunomycin, vincristine, prednisone and rituximab).
Follow-up clinical evaluation and computerized tomogra-
phy scans, 8 months post-chemotherapy, were consistent
with complete remission, and the patient remains disease
free 7 years after diagnosis.Case 2
A 68-year-old female with a history of paroxysmal atrial
fibrillation and progressive polyneuropathy, diagnosed as
Guillain-Barre Syndrome, was initially treated with steroids,
intravenous immune globulin and plasmapharesis, with good
response. She presented to our institution with exacerbation
of polyneuropathy requiring intubation. Given the atypical
relapsing course of her disease, a search for an underlying
neoplastic disorder was initiated. Bone marrow biopsy and
peripheral blood flow cytometrywere indicative of a low-grade
B-NHL. Serum protein electrophoresis detected monoclonal
IgM kappa paraprotein (1.4 g/dL). A positron emission tomog-
raphy scan showed hypermetabolic lesions in the spleen and
splenic hilar lymphadenopathy. A diagnosis of SMZL with
transformation to DLBCL was rendered on evaluation of the
splenectomy specimen. Chemotherapy with R-CHOP regimen
was initiated. Repeat positron emission tomography scan and
clinical evaluation after completion of six cycles of chemother-
apy showed no evidence of disease. The patient remains in
complete remission 2.5 years after diagnosis.Methods
Formalin-fixed and paraffin-embedded tissue sections were
stained with hematoxylin and eosin for morphologic
evaluation. Immunohistochemical staining was performed
with the following antibodies: CD3, CD5, CD20, CD43,
BCL2, BCL6, CD10 (Leica Biosystems, Buffalo Grove,
IL) and CD79a, Ki-67, MUM1 and p53 (Ventana Medical
Systems, Oro Valley, AZ), after moist heat induced antigen
retrieval. The Envision plus system (DAKO, Carpinteria,
CA) and diaminobenzidine were used for visualization,
according to standard methods. In situ hybridization for
kappa and lambda light chain mRNA was performed
according to standard methods (Ventana Medical Systems,
Oro Valley, AZ). Four-colour flow cytometry of the fresh
tissue samples was performed using a comprehensive panel
of antibodies with FACSCalibur (Becton Dickinson, San
Diego, CA). Data were analysed using Cellquest software
(Becton Dickinson). G-banding was performed on meta-
phases obtained after overnight (12–15 h), unstimulated
cultures, using standard procedures and karyotypes, were
described according to the International System for HumanCopyright © 2014 John Wiley & Sons, Ltd.Cytogenetic Nomenclature (ISCN 2009) [12]. Fluorescence
in situ hybridization (FISH) analysis was performed on
methanol–acetic acid fixed cells using dual-colour break-apart
probes for MLL/KMT2A, IGH, BCL2 and BCL6, as well as
ATM/TP53 locus-specific probes (VYSIS, Downers Grove,
IL) according to standard protocols. Fluorescence signals were
captured after counterstaining with DAPI using the Cytovision
Imaging system attached to a Nikon Eclipse 600 microscope
(Applied Imaging, Santa Clara, CA) and hybridization signals
were scored in 200–500 cells. Polymerase chain reaction
(PCR) analysis was performed to detect immunoglobulin
heavy chain (IGH) gene rearrangement using DNA extracted
from formalin-fixed, paraffin-embedded tissues [13].
This study was performed in accordance with the regula-
tions of the Columbia University Human Research Protection
Program, adhering to the ethical standards promulgated in
the Helsinki Declaration, and a protocol approved by the
Institutional Review Board of Columbia University, New
York, USA.Results
Case 1
Examination of the thyroid gland revealed a firm mass with
vague lobulation, which on sectioning showed a diffuse
infiltrate of large centroblast-like cells and residual thyroid
follicles (Figure 1A). Scattered mitotic figures and apopto-
tic cells, as well as foci of coagulative necrosis, were seen.
No low-grade lymphoma component or lymphoepithelial
lesions were identified. Immunohistochemistry and flow
cytometry findings confirmed the diagnosis of primary
thyroid DLBCL, non-germinal centre B-cell (non-GCB)
phenotype (Figure 1B–1D, Table 1). Approximately,
60% of the neoplastic cells showed aberrant nuclear p53
staining, and the lymphoma had a high Ki-67 proliferation
index (90%). A clonal product was identified on PCR
analysis for IGH gene rearrangement.
G-band analysis demonstrated a complex karyotype
(Figure 1E, Table 1). FISH analysis detected KMT2A translo-
cation in 94% cells (Figure 1F and 1G) and IGH translocation
in 95% cells using break-apart probes. The signal patterns of
the IGH and KMT2A probes on metaphase spreads confirmed
the karyotypic observation of t(11;14)(q23;q22). However,
the breakpoint involving KMT2A was unusual, as the 3′
(distal, orange)KMT2A signal that translocated to der(14) also
had a tiny signal from the 5′(proximal, green) KMT2A probe.
Thus, the breakpoint in the KMT2A gene was proximal to the
conventional breakpoint that completely separates the 5′
(green) signal from the 3′ (orange) signal. In addition, an extra
copy of the 3′ (orange)KMT2A probewas also seen on a small
acrocentric chromosome (Figure 1G). These results suggest
that the KMT2A gene was involved in complex rearrange-
ments with IGH and another unidentifiable gene/locus. NoHematol Oncol 2015; 33: 239–246
DOI: 10.1002/hon
Figure 1. (A) Large centroblast-like cells infiltrating the thyroid gland (hematoxylin and eosin, 400×) display CD20 (B), MUM1 (C) and
BCL6 (D) expression, consistent with DLBCL, non-GCB phenotype. E, G-band karyotype, arrows indicate t(11;14)(q23;q32) and del
(4)(p12). Fluorescence in situ hybridization analysis using KMT2A break-apart probes in interphase nuclei (F) and a metaphase spread
(G) shows one yellow signal (normal, non-rearranged KMT2A), one green signal (5′ rearranged), one orange and faint green signal
(3′ atypical 5′ proximal break point) (white arrow) and one additional orange signal (3′ rearranged KMT2A present on a small acrocentric
chromosome), findings consistent with a complex KMT2A translocation
241MLL/KMT2A translocations in diffuse large B-cell lymphomasBCL2 or BCL6 rearrangements were detected. FISH analysis
using ATM/TP53 probes revealed deletion of one copy of
TP53 in 95% of cells, consistent with the karyotypic identifi-
cation of loss of chromosome 17.Case 2
The spleen had a diffuse, micronodular appearance on
gross examination, and two discrete large parenchymal
nodules as well as a hilar mass were visualized. SectionsCopyright © 2014 John Wiley & Sons, Ltd.of the hilar lymph node and parenchymal nodules showed
diffuse infiltrates of large lymphocytes with immunoblastic
and focal plasmacytoid features (Figure 2A). The splenic
infiltrates were surrounded by fibrous bands and abundant
hemosiderin-laden macrophages were present. Scattered
apoptotic debris, mitoses and foci of coagulative necrosis
were observed. Immunohistochemistry and flow cytometry
confirmed the presence of a DLBCL exhibiting a non-GCB
phenotype (Figure 2C–2F, Table 1). The proliferation index
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Figure 2. Splenic mass displaying diffuse large B-cell lymphoma (DLBCL) (A) and adjacent spleen exhibiting splenic marginal zone lymphoma (B)
(insert shows dim CD43 expression on neoplastic cells) (hematoxylin and eosin, 400×). DLBCL expresses CD20 (C), MUM1 (D) and BCL6 (E),
consistent with a non-GCB phenotype. (F) Neoplastic cells show kappa light chain restriction by in situ hybridization for immunoglobulin light chain
mRNA (insert shows rare cells expressing lambda light chainmRNA).G,G-band karyotype obtained from splenicDLBCL. Arrows indicate t(3;11)
(p23;q23),+3, +9 and +18. (H) Fluorescence in situ hybridization analysis using KMT2A break-apart probe on ametaphase spread shows one yellow
signal (intact KMT2A locus) on normal chromosome 11, one green signal (rearranged, 5′ end) on the short arm of abnormal chromosome 3 and
one orange signal (rearranged 3′ end) on the long arm of abnormal chromosome 11, features consistent with KMT2A translocation
243MLL/KMT2A translocations in diffuse large B-cell lymphomasneoplastic cells showed aberrant nuclear p53 staining.
Elsewhere, the splenic parenchyma showed variably sized
white pulp lymphoid nodules that mostly lacked germinalCopyright © 2014 John Wiley & Sons, Ltd.centres and were comprised of small lymphocytes
(Figure 2B) that displayed variable plasmacytoid features
and had the following phenotype: CD20+, CD79a+, BCL6-,Hematol Oncol 2015; 33: 239–246
DOI: 10.1002/hon
244 T Gindin et al.CD10-, MUM1(subset)+, CD5-, and CD43(subset)+
(Figure 2B (insert)). Staining for Ki-67 showed a low
proliferation index (10%). These features were suggestive
of SMZL.
G-band analysis of the large cell lymphoma demon-
strated a complex karyotype (Figure 2G, Table 1). FISH
analysis using the KMT2A break-apart probe detected
KMT2A translocation in 66.4% cells (Figure 2H). FISH
analyses using IGH, BCL2 or BCL6 break-apart probes
were negative for translocations. However, three copies
of BCL2 were observed in 38% cells, with multiple copies
(up to 10/cell) noted in a subclone comprising 46% cells.
The BCL6 probe showed three copies in 82% cells. These
findings confirmed the presence of trisomy 3 and 18 seen
on karyotype analysis. FISH using ATM/TP53 probes
revealed deletion of one copy of TP53 in 77% of cells. A
sample corresponding to the SMZL showed a normal
karyotype and no KMT2A gene translocation. However,
trisomy 18 was detected in 7% of cells using the BCL2 probe.
Clonal products of identical molecular weight were
detected by PCR analysis for IGH gene rearrangement in the
SMZL and DLBCL components. On the basis of the morpho-
logic, phenotypic, cytogenetic and molecular analyses, the
findings were indicative of large cell transformation of SMZL.Discussion
We describe two cases of DLBCL harbouring KMT2A
translocations. A review of the literature disclosed only
four prior reports of B-NHL associated with KMT2A trans-
locations (Table 1). In the largest series of NHL with
karyotype abnormalities involving the 11q23 region, three
of 20 (15%) cases harboured KMT2A translocations,
including one case each of follicular lymphoma, Burkitt lym-
phoma and DLBCL [11]. No morphologic and phenotypic
details were reported for these cases, and no information
regarding treatment and outcomes was provided. An EBV-
associated post-transplant Burkitt-like lymphoma with
KMT2A translocation was also described in a 28-month male
patient who presented with abdominal lymphadenopathy
and involvement of the liver and kidney, 19months after
liver transplantation [8]. Only limited phenotypic informa-
tion was provided, but the patient was in complete remission
15months after withdrawal of immunosuppression and
administration of combination chemotherapy (Table 1).
Neither primary thyroid DLBCL, nor large cell transfor-
mation of SMZL with abnormalities involving KMT2A
have been reported previously. DLBCL and marginal zone
lymphomas, comprise up to 90% of all primary thyroid
lymphomas, and an association between DLBCL and thy-
roid marginal zone lymphoma and chronic lymphocytic
thyroiditis is well recognized [14,15]. Molecular pathways
of thyroid lymphoma development are thought to differ
from lymphomas occurring at other sites, but the molecularCopyright © 2014 John Wiley & Sons, Ltd.or genetic alterations underlying primary, de novo DLBCL
of the thyroid are not well understood. According to the
Mitelman Database of Chromosome Aberrations and Gene
Fusions in Cancer [16] cytogenetic aberrations of only six
cases of primary thyroid DLBCL have been reported.
The cases harbouring structural changes included two with
t(8;14)(q24;q32) involving the cMYC and IGH genes and
one displaying t(12;14)(p11.2;q32.3). Numerical chromo-
somal abnormalities included loss of the X chromosome
and trisomy 22. Data regarding genetic or molecular alter-
ations associated with large cell transformation of SMZL
are even sparser. In a series of 12 SMZL transforming to
DLBCL, cytogenetic findings were described for seven cases
[17]. Six of seven cases showed chromosome abnormalities,
with recurrent 7q losses observed in 42% and 1q32 alter-
ations in 29% of cases. The lack of molecular alterations of
TP53 and infrequent loss of the p16 protein in the subset
of cases analyzed, led the investigators to speculate that
the pathways of SMZL transformation might be different
from those described for other low-grade B-NHL [17].
KMT2A is a member of the lysine N-methyltransferase
family of genes that encode SET domain containing pro-
teins, which provide an epigenetic mark at gene regulatory
regions, especially enhancers, by modifying (methylating)
lysine-4 of histone 3. This change is required for the activa-
tion of a large number of target genes involved in hemato-
poiesis and development, most notably the homeobox
(HOX) gene family [18]. KMT2A plays important roles in
a variety of cellular functions, including DNA damage
response and cell cycle control, by regulating cell cycle
checkpoints and preventing chromatid errors [19,20]. A
multitude of KMT2A aberrations have been documented
in hematologic neoplasms, including translocations, partial
tandem duplications, amplifications and mutations, which
arise via diverse mechanisms and have different functional
consequences [6,21]. KMT2A translocations or rearrange-
ments represent the most common abnormalities that result
in the formation of chimeric transcripts with leukemogenic
potential [22]. To date, at least 121 different KMT2A translo-
cations and 79 KMT2A fusion partner genes have been
identified in acute leukemias and myeloid neoplasms [23].
The resulting chimeric proteins differentially impact the
phenotype and outcome of the neoplasms by interacting with
various molecular complexes, regulating different networks
of genes, and/or having differential effects on common
targets [20]. HOXA9 and its transcriptional co-factor MEIS1
are the most critical downstream targets deregulated by
KMT2A fusion proteins, as their co-expression is sufficient
to transform cells and induce acute myeloid leukemia [24].
Additionally, KMT2A-fusion proteins exhibit resistance to
degradation by the ubiquitin-proteasome system, which
may contribute to their leukemogenic potential [19].
The functional consequences of KMT2A translocations
in mature B-NHL, including the two DLBCL presentedHematol Oncol 2015; 33: 239–246
DOI: 10.1002/hon
245MLL/KMT2A translocations in diffuse large B-cell lymphomasherein are not known at present. Deregulated expression of
KMT2A via juxtaposition with the immunoglobulin heavy
chain, or another, enhancer could result in a gain of func-
tion. However, other possibilities include, loss of function
due to structural changes, such as deletions within KMT2A,
via a dominant negative effect by interfering with wild-
type KMT2A, or altered function due to the generation of
fusion transcripts. Further in vitro studies, modelling B-
NHL associated KMT2A translocations, are required to
determine if these rearrangements alter associations between
KMT2A and other cofactors or signalling complexes, as has
been observed in acute leukemias harbouring KMT2A trans-
locations and also for products of other genes targeted by re-
current translocations in subsets of NHL.
In contrast to translocations, amplifications of the 11q23
region including the KMT2A locus have been documented
more frequently in B-NHL. Starostik et al. demonstrated
high level amplifications of KMT2A in five cases of
primary gastric DLBCL using comparative genomic
hybridization and FISH analyses [25]. Two additional reports
described KMT2A amplifications in one case each of a
plasmablastic lymphoma [10] and an intravascular large
B-cell lymphoma [9]. The former exhibited five copies
of KMT2A by cytogenetic analysis, occurred in an HIV+
patient and responded to standard chemotherapy [10]. Of
note, amplifications of the chromosome 11q23 region have
been described in intravascular large B-cell lymphomas;
however, KMT2A amplification has been confirmed in only
one case by FISH analysis [9]. If the amplifications are
established to involve wild-type KMT2A, then such
abnormalities could result inKMT2A gain of function and have
similar pathogenetic consequences as suggested for myeloid
neoplasms associated with KMT2A amplifications, but differ-
ent from those proposed for neoplasms harbouring partial
tandem duplications [21].
Further molecular studies analysing the chromosome
breakpoints are required to determine the plausible mecha-
nisms responsible for generating KMT2A translocations in
mature B-NHL. Acute leukemia and MDS associated
KMT2A translocations arise due to inhibition of the enzyme
DNA topoisomerase II by chemotherapeutic drugs [26]. Our
patients had no history of exposure to topoisomerase II inhib-
itors, as well as alkylating agents or radiation, which have
also been implicated in the genesis of KMT2A translocations.
The mechanistic basis of other types ofKMT2A aberrations in
leukemias, MDS and B-NHL is not well understood. KMT2A
abnormalities have been associated with a poor prognosis in
MDS and acute leukemias [6]. On the contrary, both our
DLBCL as well as previously reported B-NHL subtypes
associated with KMT2A translocations or amplifications
responded well to standard chemotherapy regimens and
showed complete remission, albeit with variable follow-up
durations, ranging from 15months to 7 years (Table 1).
Recent studies using high resolution genomic ap-
proaches have uncovered aberrations (mostly mutations)Copyright © 2014 John Wiley & Sons, Ltd.in several epigenetic modifier genes, especially those
regulating histone acetylation and methylation in lympho-
mas, as well as other malignancies [4,5,27,28]. Of note,
these studies identified mutations in multiple other lysine
N-methyltransferase gene family members. Loss of function
mutations inKMT2D/MLL2were the most frequent reported
events in DLBCL (up to 32% of cases), but their role in
DLBCL pathogenesis is not known at present [4,5].
In summary, our and the few previously reported cases
document the occurrence of KMT2A translocations in mature
B-NHL, besides acute leukemias and MDS, and suggest that
KMT2A aberrations represent, as yet, underappreciated (and
additional) mechanisms deregulating the function of epige-
netic modifier genes in DLBCL. Future investigations of
B-NHL associated with chromosome 11q23 aberrations are
warranted to shed light on the frequency of KMT2A abnor-
malities in different disease subtypes, better understand
the stage of acquisition of these alterations and elucidate
their functional consequences.Conflict of interest
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